Daily Brief : July 14: FDA clears psychedelic trial path, Space Force expands launch vendors

HEADLINE

FDA hands psychedelic drug developers a trial blueprint while Space Force opens $5.6 billion in launch contracts to commercial startups, signaling regulatory confidence in unconventional solutions.

THE BIG PICTURE

Two separate institutions, the FDA and the Pentagon, are removing friction from sectors that have moved faster than their gatekeepers could accommodate. The FDA's final guidance on psychedelic drug investigations, published yesterday, codifies a pathway that has been de facto open for years but lacked clarity. Simultaneously, the Space Force is widening its vendor base for critical national security missions, bringing in companies like Impulse Space and Relativity Federal that were barely on the radar five years ago. Both moves suggest institutional acceptance that centralized infrastructure can't keep pace with innovation and that distributing authority to capable private actors beats holding the line.

WHAT HAPPENED

The FDA published final industry guidance titled 'Psychedelic Drugs: Considerations for Clinical Investigations' on Monday, July 13, with the guidance entering the Federal Register on Tuesday. The document formalizes trial design, dosing protocols, and safety monitoring for clinical investigations of psychedelic compounds, removing a major uncertainty that has slowed the sector. Until now, companies developing psilocybin and other psychedelic therapies have worked from draft guidance issued in 2018 and ad hoc FDA feedback. The final version gives drug developers a clear rulebook, likely accelerating Phase 2 and Phase 3 trial starts across multiple companies in the space.

The Space Force awarded NSSL Phase 3 Lane 1 IDIQ contracts, each worth up to $5.6 billion in total ceiling, to Impulse Space and Relativity Federal, with announcements flowing from U.S. Space Force Space Systems Command on July 7 and press releases from the companies on July 9. This marks a significant shift: Impulse Space specializes in upper-stage spacecraft and in-space logistics, while Relativity Federal focuses on 3D-printed rockets. For the first time, an upper-stage operator is being treated as a prime contractor on a national security vehicle, a recognition that launch architecture has matured beyond first-stage providers. The contracts will allow the two firms to compete for task orders alongside established players and significantly expand the Space Force's optionality for critical missions.

Arkenstone Defense emerged from stealth on July 7 with a $35 million seed round. The company develops advanced stealth technologies for defense applications, though specific technical details remain under wraps. The funding marks continued investor confidence in defense deeptech, particularly in sensing and evasion technologies that U.S. military procurement has traditionally outsourced or built in-house.

WATCHING

Watch for the first NSSL Phase 3 task order awards to Impulse or Relativity within the next 60 days, and track initial psychedelic trial enrollments at companies like Compass Pathways and MindMed now that the FDA guidance has settled. Both will signal how quickly institutions can convert regulatory clarity into operational momentum.